Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines

BACKGROUND: Multidrug-resistant TB (MDR-TB) is a growing problem in the effort to end the global TB epidemic. In 2019, the WHO adopted a new standardised regiment for MDR-TB, consisting of only oral medications. METHODS: We estimated the impact of the new guidelines on the costs of TB treatment in E...

Descripción completa

Detalles Bibliográficos
Autores principales: Feuth, T., Patovirta, R-L., Grierson, S., Danilovits, M., Viiklepp, P., Aaltonen, H. K., Vauhkonen, M., Pehme, L., Vasankari, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259121/
https://www.ncbi.nlm.nih.gov/pubmed/34183100
http://dx.doi.org/10.5588/ijtld.20.0892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259121/
https://www.ncbi.nlm.nih.gov/pubmed/34183100
http://dx.doi.org/10.5588/ijtld.20.0892

Ejemplares similares